Partnering in Central Nervous System Diseases
Our growing portfolio of partnerships in Central Nervous System diseases aims to address the significant need for new treatments across a range of neuropsychiatric disorders and includes partnerships with both academia and industry. We are actively pursuing new early-science collaborations in our areas of partnering interest and look forward to expanding our community of innovation partners.
Our experience
The development of new treatment options for Neuropsychiatric diseases is a key priority for Boehringer Ingelheim. Our scientists, together with our innovation partners, are pursuing novel therapeutic approaches to address unmet needs across a range of major neuropsychiatric disorders.
Our approach focuses on investigating maladaptive brain circuitry underlying major untreated neuropsychiatric symptoms. In addition, we’re exploring pathological underpinnings of circuit malfunction and applying emerging GWAS (genome-wide association studies) data to find ways for early intervention in neuropsychiatric disorders. We are optimistic that this approach will lead to the development of effective treatments that can be applied across mental illness.